

APPOINTMENT US BASED NON-EXECUTIVE DIRECTOR: SIMON ARKELL

Adelaide, Australia, 30 January 2019: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the appointment of Simon Arkell as a Non-Executive Director, starting 30th January 2019.

Mr. Arkell is based in California, USA and is a hi-tech entrepreneur with a focus on Artificial Intelligence (**AI**) and software analytics technologies. He is the co-founder of seven companies, notably Predixion Software, an advanced analytics software company focused on real-time visual analytics for the Internet of Things (IoT) and real time patient risk analytics in healthcare. In 2016 Predixion was acquired by Greenwave Systems in Irvine, California, a leader in IoT device design and managed services.

More recently, Mr. Arkell co-founded Deep Lens, an AI company focused on accelerating the use of digital pathology to help match cancer patients to life saving available clinical trials. Deep Lens is adding AI-powered image detection and workflow support, telepathology, collaboration, cloud storage and built in APIs for integration by hardware and software vendors and biopharma companies. The platform is currently used by hundreds of pathologists at over 75 major institutions in 9 countries, primarily within the United States.

LBT Chairman Kate Costello said:

"The Board continues to reflect on its skill mix and composition during a time where our focus is on establishing global channels to support commercialisation of our APAS® technology. Simon's background in software and AI companies within the US facilitates a channel opportunity for LBT, especially as we focus on US expansion."

Incoming Non-Executive Director Simon Arkell said:

"Following discussions with the company over several months, I'm impressed by the AI driven APAS® technology, and impressive 10,000 patient clinical trial resulting in FDA clearance. There are dozens of institutions in the US using our Deep Lens platform and I am looking forward to helping both companies benefit from their complementary focus on the pathology market, in particular in the US market."

Simon has a BA (Econ) from University of New Mexico, and an MBA from Cal Poly (San Luis Obispo, California) where he also sits on the business school Dean's Advisory Council and the President's Committee. He is founder and MC of the Megan's Wings Orange County Gala which has raised almost \$1 million for the families of children diagnosed with cancer.

Simon is also a two time Olympian (pole vault) and in 2015 was awarded Orange County, California CEO of the year for mid-sized companies.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software, and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation. LBT's third product WoundVue® is in early development; this is a proposed automated solution to assist in the management of chronic wounds.



CONTACTS

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com